In Vitro Assessments of Antimicrobial Activity
ID: 75N93024R00024Type: Presolicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIAIDBETHESDA, MD, 20892, USA

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH (AN11)

Original Source

https://sam.gov/opp/a25d8a263b6d4d9ab2bc81cb62143001/view
Timeline
    Description

    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for the In Vitro Assessments of Antimicrobial Activity program to support in vitro testing for evaluating the therapeutic potential of compounds against infectious diseases. This initiative aims to enhance the understanding and treatment of infectious diseases by providing efficient assessment tools integrated into the product development pipeline, focusing on various pathogens including bacteria, fungi, viruses, and challenging pathogens that require innovative culturing techniques. The RFP will be available online around December 30, 2024, and proposals must be submitted via the NIAID electronic Contract Proposal Submission (eCPS) platform; interested parties can contact Alexander Beraud at alexander.beraud@nih.gov or Brian Madgey at brian.madgey@nih.gov for further information.

    Point(s) of Contact
    Alexander Beraud
    alexander.beraud@nih.gov
    Brian Madgey
    brian.madgey@nih.gov
    Files
    Title
    Posted
    75N93024R00024 - Pre-Solicitation Notice.pdf
    The National Institute of Allergy and Infectious Diseases (NIAID) is issuing a Request for Proposal (RFP # 75N93024R00024) to support in vitro testing for evaluating the antimicrobial activity of compounds. This initiative aims to enhance the understanding and treatment of infectious diseases by providing efficient assessment tools integrated into the product development pipeline. The RFP outlines several Task Areas for potential contractors, specifically targeting bacteria, fungi, viruses, and challenging pathogens that require innovative culturing techniques. Contractors will be expected to manage all aspects of the work and may collaborate with other organizations as necessary. Proposals can be submitted for multiple Task Areas; however, separate submissions will be required for each. The RFP will be available online around December 30, 2024, and submissions must occur via the NIAID electronic Contract Proposal Submission (eCPS) platform. This solicitation does not guarantee contract awards, highlighting NIAID's dedication to advancing medical countermeasures effective against priority pathogens and supporting HHS partners through crucial data provision.
    Lifecycle
    Title
    Type
    In Vitro Assessments of Antimicrobial Activity
    Currently viewing
    Presolicitation
    In Vitro Assessments of Antimicrobial Activity
    Sources Sought
    Similar Opportunities
    NIAID Virology Quality Assurance
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a comprehensive quality assurance program for virologic assays related to HIV and other viral pathogens. The objective is to ensure the validity and comparability of laboratory data through proficiency testing panels and real-time assay controls, which are critical for ongoing and future studies on infectious diseases. This program has been operational since 1988 and supports approximately 110 laboratories globally, emphasizing the importance of maintaining high standards in virologic testing. Proposals are expected to be submitted electronically via the NIAID electronic Contract Proposal Submission (eCPS) website, with the solicitation anticipated to be available on or about January 9, 2025. For further inquiries, interested parties can contact Shawnice Williams at shawnice.williams@nih.gov or Ashley Kinderdine at ashley.kinderdine@nih.gov.
    2026 NIAID DMID Omnibus Broad Agency Announcement
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and specifically the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the 2026 DMID Omnibus Broad Agency Announcement (BAA) aimed at advancing research and development of medical countermeasures against antimicrobial-resistant pathogens and viruses with pandemic potential. The BAA encompasses two primary research areas: the development of therapeutics, vaccines, and diagnostics for antimicrobial-resistant bacterial and fungal pathogens, and the creation of direct-acting antivirals for viral families of pandemic potential. This initiative is critical for addressing public health challenges related to infectious diseases and enhancing biodefense capabilities. Proposals for Research Area 001 are due by February 21, 2025, while those for Research Area 002 are due by January 21, 2025. Interested parties can reach out to primary contact Swee L. Teo at teosl@niaid.nih.gov or 240-669-5173 for further information.
    NIAID CLINICAL PRODUCTS CENTER (CPC)
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a contract to provide pharmacy and pharmaceutical oversight for clinical trials, both nationally and internationally. The primary objective of this contract is to ensure the integrity of study products, participant safety, and compliance with pharmacy and pharmaceutical regulations throughout various NIH-funded clinical trials. This opportunity is critical for maintaining high standards in public health research, as it encompasses a wide range of services including product management, regulatory document maintenance, and clinical laboratory testing. Proposals are due by January 17, 2025, with the contract expected to commence on April 1, 2026, and run through March 31, 2027, potentially extending through 2033. Interested parties can contact Deborah Blyveis at blyveisd@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov for further information.
    National Institute of Environmental Health Sciences (NIEHS) Assessment of Immunotoxicity – In Vitro and In Vivo Assessment of Immune Function
    Active
    Health And Human Services, Department Of
    The National Institute of Environmental Health Sciences (NIEHS), part of the Department of Health and Human Services, is seeking proposals for a federal contract focused on the assessment of immunotoxicity through in vitro and in vivo evaluation of immune function. The objective is to provide comprehensive research services to evaluate how selected test agents may modulate immune responses, utilizing both established and innovative methodologies to reduce animal use in toxicology studies. This contract, anticipated to be a cost-plus-fixed-fee type, is expected to be awarded by September 2025, with a base period of one year and nine optional one-year extensions. Interested parties should direct inquiries to Adam Muhsin at adam.muhsin@nih.gov and monitor the Sam.gov website for the solicitation release, which is expected no sooner than 15 days from this notice.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting proposals for Chemistry, Manufacturing, and Controls (CMC) services related to the development of drug products. The objective of this procurement is to secure high-quality formulated drug products to support preclinical, IND-enabling, and clinical studies, ensuring compliance with current Good Manufacturing Practices (cGMP). This initiative is critical for advancing therapeutic development and enhancing the drug development pipeline, which is vital for public health. Proposals are due by February 3, 2025, with a contract period extending from September 30, 2025, to July 31, 2031, and a maximum funding amount of $49,885,703. Interested parties can reach out to Michelle Cecilia at michelle.cecilia@nih.gov or Valerie Whipple at valerie.whipple@nih.gov for further information.
    Development of Radiation/Nuclear Medical Countermeasures (MCMs) And Biodosimetry Devices
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the development of Radiation/Nuclear Medical Countermeasures (MCMs) and biodosimetry devices. The primary objectives are to create MCMs that mitigate normal tissue injuries from ionizing radiation and to advance biodosimetry methods to enhance triage and treatment during radiation emergencies, with each proposal focusing on one of these goals. This initiative is crucial for national preparedness against potential radiological incidents, as it aims to improve the response to radiation exposure and associated health risks. Proposals are due by March 19, 2025, and interested parties must register in the System for Award Management (SAM); the estimated cost and fixed fee for the contract are to be determined. For further inquiries, contact Albert Nguyen at nguyenal@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov.
    Pathology Support for the National Institute of Environmental Health Sciences
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting proposals for pathology support services for the National Institute of Environmental Health Sciences (NIEHS) under solicitation number 75N96025R00003. The procurement aims to secure comprehensive pathology-related services, including technical support, histopathological evaluations, and assistance with reporting and publication of findings, with a contract period anticipated from July 2025 to July 2026, and options for extensions up to July 2035. This initiative is crucial for enhancing NIEHS's research capabilities while ensuring compliance with federal regulations regarding human subjects and promoting inclusivity in research practices. Interested parties must submit their proposals by 4:00 PM EST on January 6, 2025, and can direct inquiries to Sue McKenzie at sue.mckenzie@nih.gov or Erica Kitzmiller at erica.kitzmiller@nih.gov.
    Brand Name Biological Product
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking quotes for a brand name biological product under solicitation number RFQ-NIAID-25-2251721. The procurement involves the acquisition of specific biological supplies, including various anti-human antibodies, to support the National Institute of Allergy and Infectious Diseases (NIAID) in its research efforts. These products are critical for advancing biomedical research and ensuring the availability of high-quality reagents for scientific studies. Interested vendors must submit their offers by December 22, 2024, at 10:00 AM EST, and can direct inquiries to Calvin Robinson at calvin.robinson@nih.gov.
    Public Health Industrial Base Capabilities and Capacities: Anti-Microbials
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services (HHS) is seeking industry partners to provide information regarding domestic production capabilities related to anti-microbials under the Defense Production Act Title III Program. The objective of this Request for Information (RFI) is to identify gaps in the Public Health Industrial Base (PHIB) and enhance national defense resources by focusing on the production of essential medicines and medical countermeasures sourced domestically. Respondents are encouraged to share insights on their manufacturing processes, regulatory compliance, and infrastructure, as well as past supply chain disruptions and investment needs, with responses due by January 6, 2025, at 10 AM ET. Interested parties should submit their responses to Chris Newell at IBMSC-Submissions@hhs.gov.
    In Vitro Biological Reagents
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), intends to negotiate a sole source procurement with Becton, Dickinson and Company for various in vitro biological reagents essential for research purposes. The procurement includes specific quantities of antibodies and reagents, such as Hu CD183 BV711 and Hu IL-13 BV421, along with shipping and handling to be delivered to Gaithersburg, Maryland. This procurement is justified under the authority of 41 U.S.C. 1901 (a)(1), indicating that only one responsible source can meet the agency's requirements. Interested parties may submit a capability statement via the NIAID electronic Simplified Acquisition Submission System (eSASS) by December 30, 2024, with all submissions considered at the Government's discretion. For further inquiries, contact Leah Hinson at leah.hinson@nih.gov.